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Abstract
Introduction During septic shock, resistance to the
haemodynamic effects of catecholamine vasopressors and
inotropes is a well-recognised marker of mortality risk. However,
the specific cardiovascular or metabolic response elements that
are most closely associated with outcome have not been well
defined. The objective of this study was to assess
cardiovascular and metabolic responses to dobutamine as
correlates of outcome in patients with severe sepsis or septic
shock.
Methods A prospective, non-randomised, non-blinded
interventional study of graded dobutamine challenge (0, 5, 10,
and 15 μg/kg/min) in adult patients who had undergone
pulmonary artery catheterisation within 48 hours of onset of
severe sepsis or septic shock (8 survivors/15 non-survivors)
was performed. Radionuclide cineangiography during graded
infusion was used to determine biventricular ejection fractions at
each increment of dobutamine.
Results In univariate analysis, a variety of cardiovascular or
haemodynamic and oxygen transport or metabolic variables (at
the point of maximum cardiac index response for a given
subject) were associated with survival including: increased
stroke volume index (p = 0.0003); right ventricular end-diastolic
volume index (p = 0.0047); left ventricular stroke work index (p
= 0.0054); oxygen delivery index (p = 0.0084); cardiac index (p
= 0.0093); systolic blood pressure/left ventricular end-systolic
volume index ratio (p = 0.0188); left ventricular ejection fraction
(p = 0.0160); venous oxygen content (p = 0.0208); mixed
venous oxygen saturation (p = 0.0234); pulse pressure (p =
0.0403); decreased pulmonary artery diastolic pressure (p =
0.0133); systemic vascular resistance index (p = 0.0154);
extraction ratio (p = 0.0160); and pulmonary vascular resistance
index (p = 0.0390). Increases of stroke volume index of greater
than or less than 8.5 mL/m2 were concordant with survival or
death in 21 of 23 cases. Multivariate profile construction
showed stroke volume index as the dominant discriminating
variable for survival with the systolic blood pressure/left
ventricular end-systolic volume index ratio alone among all other
variables significantly improving the model.
Conclusion Survivors maintain cardiac responsiveness to
catecholamine stimulation during septic shock. Survival from
severe sepsis or septic shock is associated with increased
cardiac performance and contractility indices during
dobutamine infusion. Further studies are required to determine
whether these parameters are predictive of outcome in a larger
severe sepsis/septic shock population.
CI = cardiac index; CO = cardiac output; CvO2 = venous oxygen content; CVP = central venous pressure; DO2I = oxygen delivery index; dPAP = 
diastolic pulmonary artery pressure; ECG = electrocardiographic; EDV = end-diastolic volume; EF = ejection fraction; ESV = end systolic volume; 
FiO2 = inspired oxygen fraction; HR = heart rate; LVEDVI/PWP = left ventricular end-diastolic volume index: pulmonary wedge pressure ratio; LVEF 
= left ventricular ejection fraction; LVSWI = left ventricular stroke work index; MAP = mean arterial pressure; mPAP = mean pulmonary artery pressure; 
MVO2 = mixed venous oxygen saturation; OER = oxygen extraction ratio; PaO2 = arterial partial pressure of oxygen; PAP = pulmonary artery pressure; 
pCO2 = partial pressure of carbon dioxide; pO2 = partial pressure of oxygen; PP = pulse pressure; PWP = pulmonary wedge pressure; PVR = pul-
monary vascular resistance; PVRI = pulmonary vascular resistance index; RAP = right arterial pressure; RVEDV = right ventricular end-diastolic vol-
ume; RVEDVI/RAP = right ventricular end-diastolic volume: right atrial pressure ratio; RVEF = right ventricular ejection fraction; RVSWI = right 
ventricular stroke work index; sBP/LVESVI = peak systolic pressure: left ventricular end-systolic volume index ratio; sPAP/RVESVI = peak systolic 
pulmonary artery pressure: SV = stroke volume; SVI = stroke volume index; SVR = systemic vascular resistance; SVRI = systemic vascular resistance 
index; VO2I = oxygen consumption index; right ventricular end-systolic volume index ratio.Critical Care    Vol 12 No 2    Kumar et al.
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Introduction
The cardiovascular profile of septic shock has been well
defined over the last 30 years. One of the major areas of inves-
tigation has been the cardiovascular correlates of outcome.
Early clinical studies, prior to the widespread adoption of the
balloon-tipped pulmonary artery flotation catheter with ther-
modilution capability in the 1980s, tended to suggest that fatal
sepsis and septic shock were characterised by a low cardiac
output (CO) and high systemic vascular resistance (SVR) [1].
However, the concept of septic shock as a hyperdynamic cir-
culatory state characterised by high cardiac output and low
systemic vascular resistance eventually became well estab-
lished [2,3]. Several baseline cardiovascular variables have
been proposed to differentiate between survivors and non-sur-
vivors of septic shock including heart rate (HR), CO, SVR and
oxygen delivery index (DO2I) [4-7]. Studies using radionuclide
cineangiography and volumetric echocardiography have fur-
ther demonstrated an association between survival and biven-
tricular dilatation and ejection fraction (EF) depression [3,8-
10]. Evidence has also accumulated suggesting that fatal sep-
tic shock is associated with decreased responsiveness to fluid
resuscitation [11,12].
Bedside experience and several clinical studies suggest that
blunted cardiovascular responsiveness to catecholamine sup-
port is also a marker of high risk of death in sepsis and septic
shock [13]. However, the relationship of ventricular ejection
fraction and/or ventricular volume responses and other ven-
tricular volume-related cardiovascular variables under dob-
utamine stress to survival in sepsis and septic shock is
undefined. This study was designed to assess ventricular and
cardiovascular performance, oxygen transport, and oxygen
delivery responses during dobutamine challenge and their
association with survival in sepsis.
Materials and methods
This study received Institutional Review Board approval.
Informed consent was obtained from all subjects or appropri-
ate representatives prior to enrolment.
Adult (more than 18 years of age) Intensive Care Unit patients
were recruited into this prospective, non-randomised, open
interventional study. In order to be eligible, patients were
required to have developed severe sepsis or septic shock
within the preceding 48 hours and to have both a pulmonary
artery catheter and arterial pressure catheter in place (based
on clinical requirements as defined by the attending physi-
cian). Study eligibility was further contingent on confirmation
of correct placement of the pulmonary artery catheter based
on appropriate pressure traces on insertion and position on
chest radiography.
The presence of severe sepsis was defined by 1991 SCCM/
ACCP Consensus Statement on Sepsis Definitions [14].
These criteria included: the presence of suspected or docu-
mented infection; three of the following four systemic inflam-
matory response elements temperature >38°C or <36°C,
heart rate >90 beats/min, respiratory rate >20 breaths/min or
PaCO2 <32 mm Hg and white blood cell count >12,000 cells/
mm3, <4,000 cells/mm3 or >10 per cent immature (band)
forms; and evidence of at least one organ failure.
Septic shock was defined by the presence of post-fluid resus-
citation hypotension (mean arterial pressure <65 mmHg)
necessitating vasopressor support.
Patients with known ischemic cardiac disease and mixed
shock states with clinically significant primary cardiogenic,
haemorrhagic or pulmonary embolic elements were excluded.
After consent was obtained, each patient underwent graded
dobutamine challenge as follows: If required, subjects initially
received saline infusion to a pulmonary artery wedge pressure
(PWP) of 15 mmHg as required because pilot studies had
shown the potential for significant hypotension with dob-
utamine absent adequate intravascular volume as evidenced
by PWP of 15 or higher. After documentation of a PWP of 15
mmHg or higher, baseline haemodynamic and vital parameters
(on clinically indicated doses of vasopressors) were obtained.
These included heart rate (HR), systemic arterial pressures,
central venous pressure (CVP), pulmonary artery pressure
(PAP), pulmonary wedge pressure (PWP) and CO. Thermodi-
lution cardiac outputs were measured by the averaging of
three of four successive injections of 10 mL of cold (6 to
10°C) dextrose 5 per cent in water at end-expiration (with the
outlying values discarded). Recorded values for PAP, PWP
and right atrial pressure (RAP) were also obtained at end-expi-
ration from graphic recordings. Right and left ventricular ejec-
tion fractions (EFs) were assessed through first-pass gated
technetium99 cineangiography as described below. In addi-
tion, simultaneous arterial and mixed venous blood samples
(distal pulmonary artery port) were obtained for analysis of the
serum pH, partial pressure of oxygen (pO2), partial pressure of
carbon dioxide (pCO2), and oxygen saturation (Bayer-CIBA
Model 865, Tarrytown, NY).
After baseline values were obtained, a graded dobutamine
challenge was performed. Dobutamine infusion through the
pulmonary artery catheter introducer port was initiated at 5 μg/
kg/min. After 15 minutes, repeat non-invasive and invasive
haemodynamic parameters were obtained over approximately
five minutes. At this time, subjects also underwent repeat first
pass radionuclide assessment of biventricular ejection frac-
tions and arterial and mixed venous blood gas analysis. The
dobutamine infusion rate was increased by 5 μg/kg/min at 20Available online http://ccforum.com/content/12/2/R35
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minute intervals to a maximum of 15 μg/kg/min with the
assessment process repeated during the final five minutes of
each interval. During the infusion, fluid and additional vaso-
pressor support (beyond baseline needs) to maintain a mini-
mum PWP of 15 mmHg and a mean arterial pressure (MAP)
of 65 mmHg was mandated; however, no subject required
such support. During the period of the study environmental
stimulation was minimised. All subjects were continuously
monitored with continuous electrocardiographic (ECG) moni-
toring and pulse oximetry according to standard protocol in
the intensive care unit. The protocol required discontinuation
of dobutamine if any transient adverse effects were noted
including significantly increased ventricular ectopy or
decreased blood pressure. After study completion, dob-
utamine was tapered over 20 minutes and then discontinued.
The patient's subsequent intensive care and hospital course
were directed by normal clinical practice.
Radionuclide Cineangiography
Sequential measurement of biventricular ejection fraction was
performed by repeat first-pass radionuclide cineangiography
using technetium99-DPTA. Tc99-DPTA was injected as a tight
bolus into the central veins using the pulmonary artery catheter
introducer. In this study, the baseline radionuclide tracer dose
was 2 mCi with subsequent increments to 5, 12 and 25 mCi.
The study was performed in a 30° right anterior oblique projec-
tion with a slant hole collimator fitted on to a small field gamma
camera interfaced with a dedicated computer system (ICON,
Siemens, Gammasonic). The data was acquired in frame
mode with 440 frames, each of 60 milliseconds duration. The
first transit cardiac data was reformatted into a multi-gated
study using the subject's electrocardiogram recorded with the
first pass data. This method provides independent cinematic
display of the right as well as left ventricle. Ejection fractions
(EFs) are calculated from the reformatted gated first pass
studies using standard dual region of interest and background
correction [15,16].
Stroke volume (SV) was derived by dividing thermodilution CO
by the concomitant HR. End-diastolic volume (EDV) was
obtained by dividing SV by EF and end-systolic volume (ESV)
was calculated as EDV-SV. SVR was calculated as
79.9(MAP-RAP)/CO and pulmonary vascular resistance
(PVR) as 79.9(mPAP-PWP)/CO where MAP = mean arterial
pressure and mPAP = mean pulmonary artery pressure.
Where appropriate, cardiovascular variables were indexed to
body surface area.
Data analysis
Haemodynamic and oxygen transport/consumption variables
at the baseline and at each dobutamine infusion rate were
pooled for all subjects to derive means and standard errors of
the mean. The infusion rate at the point of maximum cardiac
index (CI) during dobutamine administration was determined
for each subject and the corresponding haemodynamic/clini-
cal/oxygen metabolism values at that point were used for com-
parison to baseline (before dobutamine but after fluid
resuscitation) values. Haemodynamic values at the point of
maximum CI response were compared to pre-dobutamine infu-
sion baseline values as correlates of survival to hospital dis-
charge using two-tailed paired Student's t-test analysis.
Fisher's Exact test was used for proportional analysis and
independent-samples t-tests with Levene correction for une-
qual group variances was used for continuous measures
(Tables 1 and 2). Stepwise discriminant function methods
were used to assess the independent impact of 18 haemody-
namic and oxygen metabolism variables identified by univariate
significance test results (p < 0.2) as potentially associated
with survival outcome. Variables defined by discriminant anal-
ysis were entered as predictors in a multiple logistic regres-
sion model with outcome as the dependent variable (Table 3).
Statistical analysis was done with SPSS version 15.0.1. All
significance tests are two-tailed. Statistical significance was
defined as p < 0.05. Aggregate data is expressed as mean ±
standard deviation.
Results
Subject characteristics
Twenty-three subjects (10 male, 13 female) were recruited for
the study. Average (± standard error) age was 62.6 ± 4.0
years. Only eight of twenty-three (35 per cent) patients with
severe sepsis survived to hospital discharge. Median and
inter-quartile survival duration from the day of the study among
non-survivors was six days and two to nine days respectively.
No clinically significant adverse effects occurred during the
course of the experimental dobutamine challenge. Similar pro-
portions of subjects in each group failed to tolerate the highest
planned infusion rate (15 μg/kg/min) of dobutamine (two of
eight survivors and five of fourteen non-survivors). In all but one
case (a non-survivor), the next highest dose (10 μg/kg/min)
was tolerated.
Subject characteristics of the entire group, survivors and non-
survivors are shown in Table 1. Survivors and non-survivors
were comparable in terms of average age and gender break-
down. Twenty of twenty-three subjects required pressors at
the time of entry into the study. Both the proportion requiring
pressor support and the degree of pressor requirement was
similar in both groups. Inspired oxygen requirement was also
similar in both groups. There were no significant differences in
the two groups with respect to the arterial partial pressure of
oxygen/inspired oxygen fraction (PaO2/FiO2) ratio. The pres-
ence of renal and other individual organ failures was similar
between the groups but the mean number of organ failures at
the time of study entry was significantly higher in non-survivors.
Similarly, the Simplified Acute Physiology Score II (SAPS II) at
the time of the study were significantly higher in non-survivors;
Acute Physiology and Chronic Health Evaluation II (APACHE
II) scores were not. The most common underlying diagnoses
in non-survivors were a post-operative state and malignancy.Critical Care    Vol 12 No 2    Kumar et al.
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Among survivors, an absence of a major primary underlying
disease condition was most common. Pneumonia was the
most common underlying infection in both groups accounting
for seven of fifteen and six of eight cases in non-survivors and
survivors respectively.
Cardiovascular and haemodynamic variables
Mean difference tests for baseline and dobutamine-stimulated
haemodynamic/oxygen transport variables in survivors and
non-survivors are shown in Table 2. Among baseline cardio-
vascular/haemodynamic or oxygen transport variables, only
HR was associated with outcome (p = 0.0259). Higher values
were associated with increased mortality risk. A cut-off value
of 95 beats/min was associated with the optimal correlation
with eight mismatches, three survivors and five non-survivors
(Table 2, Figure 1a).
Survivors and non-survivors exhibited divergent responses to
dobutamine in several different areas (Table 2, Figure 2a, 3a,
4a, 5a). These areas can broadly be categorised as: 1) cardiac
performance including cardiac index (CI) and stroke volume
index (SVI); 2) oxygen consumption/delivery including mixed
venous oxygen saturation (MVO2), venous oxygen content
(CvO2), oxygen delivery index (DO2I) and oxygen extraction
ratio (OER); 3) peripheral resistance including diastolic pulmo-
nary artery pressure (dPAP), systemic vascular resistance
index (SVRI) and pulmonary vascular resistance index (PVRI);
4) left ventricular contractility including left ventricular ejection
Table 1
Baseline Clinical Characteristics and Laboratory Values of Subjects
All (n = 23) Non-survivors (n = 15) Survivors (n = 8) P value
Male/female 11 M; 12 F 7 M; 8 F 4 M; 4 F NS
Age 62.6 ± 4.0 61.4 + 5.5 64.8 ± 5.6 NS
Mechanical ventilation 17/23 13/15 4/8 NS
PO2/FiO2 171.8 ± 20.8 147.2 ± 21.1 217.9 ± 42.4 NS
Pressor use 20/23 13/15 7/8 NS
Dopamine dose (μg/kg/min) 6.8 ± 1.6 7.6 ± 2.5 5.9 + 1.8 NS
Norepinephrine dose (μg/kg/min) 0.22 ± 0.05 0.17 ± 0.05 0.30 ± 0.10 NS
Number of organ failures 5.3 ± 0.3 5.9 ± 0.3 4.3 ± 0.5 0.0138
APACHE II 27.3 ± 1.5 28.9 ± 1.8 24.4 ± 2.6 NS
SAPS 55.2 ± 2.8 61.5 ± 11.3 43.4 ± 2.7 0.0002
Serum creatinine (mg/dL) 2.4 ± 0.3 2.4 ± 0.4 2.4 ± 0.5 NS
Serum albumin (g/dL) 2.3 ± 0.1 2.2 ± 0.1 2.7 ± 0.2 0.0498
Serum bilirubin (mg/dL) 3.2 ± 1.2 4.5 ± 1.7 0.7 ± 0.1 0.0444
Platelets (× 103 per uL) 171 ± 32 119 ± 31 269 ± 60 0.0483
PT 15.9 ± 0.7 17.1 ± 0.9 13.8 ± 0.7 0.0069
Serum lactate (mmol/L) 2.7 ± 0.3 2.9 ± 0.5 2.5 ± 0.5 NS
Bacteraemia 10/23 7/15 3/8 NS
Organisms 4 S. aureus
3 E.coli
1 S. pneumoniae
1 P. mirabilis
1 C. albicans
4 S. aureus
1 E. coli
1 P. mirabilis
1 C. albicans
2 E. coli
1 S. pneumoniae
Underlying disorder 5 post-op
4 cancer
2 diabetes
1 each pancreatitis, sickle cell crisis, AIDS, 
CVA, trauma, cirrhosis, dementia, epilepsy
4 nil
4 post-op
4 cancer
1 each pancreatitis, sickle 
cell crisis, AIDS, CVA, 
trauma, cirrhosis, nil
3 nil
2 diabetes
1 each post-op, 
dementia, epilepsy
Clinical infection 13 pneu
5 bsi
2 uti
2 peritonitis
1 ssti
7 pneu
5 bsi
1 uti, ssti, peritonitis
6 pneu
1 uti
1 peritonitisAvailable online http://ccforum.com/content/12/2/R35
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Table 2
Baseline and Dobutamine-Stressed Hemodynamic/Cardiovascular and Metabolic Variables
Survivor 
Baseline 
(n = 8)
Non-survivors 
Baseline 
(n = 15)
P value: survivor 
vs non-survivor-
baseline
Survivor: 
change from 
baseline
Non-survivor: 
change from 
baseline
P value: survivor vs 
non-survivor-change 
from baseline
HR (min-1) 88.3 ± 5.1 106.7 ± 5.7 .0254 16.1 ± 4.7 14.9 ± 4.2 .8645
sBP (mmHg) 124.3 ± 6.8 114.0 ± 4.9 .2427 24.6 ± 12.6 8.3 ± 5.2 .1630
dBP (mmHg) 64.1 ± 4.2 57.6 ± 2.8 .2207 -1.6 ± 3.2 2.3 ± 2.4 .3508
PP (mmHg) 60.1 ± 6.5 56.4 ± 4.7 .6541 26.3 ± 10.4 5.9 ± 4.1 .0403
MP (mmHg) 84.2 ± 4.2 76.4 ± 2.8 .1391 7.1 ± 6.0 4.3 ± 3.0 .6225
SVI (ml/beat/m2) 31.5 ± 3.0 29.0 ± 3.0 .5663 16.4 ± 3.7 3.0 ± 1.0 .0003
CI (L/min/m2) 2.78 ± 0.32 3.01 ± 0.33 .5910 2.24 ± 0.55 0.80 ± 0.22 .0093
RAP (mmHg) 13.6 ± 1.9 14.5 ± 1.4 .7346 -0.8 ± 0.9 0.4 ± 0.8 .9405
sPAP (mmHg) 44.6 ± 4.6 40.5 ± 2.2 .4459 3.5 ± 5.1 2.2 ± 2.1 .6389
dPAP (mmHg) 22.6 ± 2.9 19.5 ± 0.8 .3253 -5.1 ± 1.8 0.6 ± 1.1 .0133
PAM (mmHg) 30.0 ± 3.3 26.5 ± 0.9 .3494 -2.3 ± 2.5 1.1 ± 1.2 .2442
PWP (mmHg) 19.8 ± 2.8 17.6 ± 1.1 .4896 -1.8 ± 1.4 -1.1 ± 0.8 .5829
PAO2 (mmHg) 95.6 ± 12.2 97.5 ± 9.4 .9034 -2.3 ± 8.2 -12.2 ± 9.2 .4518
PACO2 (mmHg) 35.6 ± 1.5 32.0 ± 2.3 .2000 -1.4 ± 0.9 -0.3 ± 0.8 .3846
O2sat (%) 95.2 ± 1.2 96.0 ± 0.7 .4750 -0.6 ± 1.2 -1.0 ± 0.7 .6463
MVO2 (% 62.3 ± 3.7 62.1 ± 2.8 .9879 8.8 ± 2.0 2.0 ± 1.6 .0234
LVEF (%) 50 ± 5 57 ± 4 .3184 11.8 ± 3.8 1 ± 2 .0160
LVEDVI (mLm2) 65.2 ± 6.5 52.7 ± 5.8 .1691 19.9 ± 7.4 7.8 ± 5.4 .1987
LVESVI (mL/m2) 33.6 ± 6.7 23.0 ± 4.4 .2535 3.5 ± 6.5 5.1 ± 5.0 .8497
LVSWI (g.m/m2) 28.3 ± 4.1 22.9 ± 2.3 .2567 22.3 ± 7.1 5.2 ± 1.4 .0054
SVRI (dynes/sec/cm2/m2) 2232 ± 314 1835 ± 170 .2728 -901 ± 246 -162 ± 150 .0154
RVEF (%) 65 ± 3 64 ± 4 .8489 4.8 ± 4.1 2.9 ± 2.5 .6793
RVEDVI (mL/m2) 48.4 ± 4.2 46.1 ± 4.7 .7194 25.2 ± 8.8 1.7 ± 2.6 .0047
RVESVI (mL/m2) 16.8 ± 2.6 17.4 ± 3.0 .8874 8.7 ± 6.7 -1.0 ± 2.4 .1125
RVSWI (g.m/m2) 6.8 ± 1.1 4.5 ± 0.6 .0916 1.8 ± 0.7 1.4 ± 0.6 .4365
PVRI (dynes/sec/cm2/m2) 322 ± 50 263 ± 45 .3910 -147 ± 39 -21.0 ± 32 .0390
CaO2 (mL/dL) 13.4 ± 1.0 12.8 ± 0.5 .6190 -0.1 ± 0.2 -0.1 ± 0.1 .8551
CvO2 (mL/dL) 8.6 ± 0.6 8.4 ± 0.6 .8161 1.3 ± 0.4 0.3 ± 0.2 .0208
DO2I (mL/min/m2) 352 ± 24 383 ± 45 .5448 301 ± 78 98 ± 29 .0084
VO2I (mL/min/m2) 122 ± 10 122 ± 6 .9967 32 ± 10 22 ± 7 .3652
sbp/lvesvi (mm Hg/mL/m2) 4.57 ± 0.73 7.33 ± 1.51 .1152 3.12 ± 1.32 0.15 ± 0.5 .0188
PAS/rvesvi (mm Hg/mL/m2) 3.06 ± 0.44 3.21 ± 0.51 .8255 0.69 ± 0.69 0.71 ± 0.90 .9877
lvedvi/pwp (mL/m2/mmHg) 3.82 ± 0.67 3.18 ± 0.38 .4123 1.52 ± 0.47 0.74 ± 0.35 .1964
RVEDVI/RAP (mL/m2/mmHg) 4.24 ± 0.89 3.44 ± 0.40 .4288 3.63 ± 2.34 0.23 ± 0.46 .0783
pH 7.38 ± 0.3 7.41 ± 0.02 .3988 0 ± 0.01 0 ± 0.01 .8820
Qs/QT 0.11 ± 0.02 0.11 ± 0.02 .8990 0.07 ± 0.05 0.03 ± 0.02 .4793
OER 0.35 ± 0.03 0.35 ± 0.03 .9928 -0.1 ± 0.03 -0.03 ± 0.01 .0160Critical Care    Vol 12 No 2    Kumar et al.
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fraction (LVEF), peak systolic pressure/left ventricular end-
systolic volume index ratio (sBP/LVESVI) and left ventricular
stroke work index (LVSWI); and 5) right ventricular lusitropy
including right ventricular end-diastolic volume (RVEDVI) and
right ventricular end-diastolic volume:right atrial pressure ratio
(RVEDVI/RAP).
Although baseline heart rate was associated with outcome,
heart rate response to dobutamine was not (Table 2, Figure
2b). Both survivors and non-survivors had similar absolute and
relative increases in heart rate with dobutamine stimulation.
Stroke volume index response had the strongest relationship
to outcome with survivors generating more than five-fold more
than the approximate mean 3 mL increase generated by non-
survivors (Table 2). Interestingly, only two patients demon-
strated a decrease in SVI (and CI) with dobutamine infusion.
Both were non-survivors. A cut-off value of 8.5 mL/m2 increase
in SVI could differentiate between survivors and non-survivors
in 21 of 23 cases with just one subject mismatched in each
group (Figure 2b). Baseline SVI did not differentiate between
survivors and non-survivors (Table 2, Figure 2a).
Other cardiac performance variables related to SVI also were
associated with survival on univariate analysis including CI and
pulse pressure (PP)(Table 2). Greater increases in DO2I,
MVO2 and CvO2 and decreased OER (variables associated
with CI) were similarly associated with improved outcome.
However, calculated oxygen consumption as reflected by
VO2I was not. Several variables associated with vascular
resistance were also found to be significantly associated with
survival on univariate analysis including decreases in SVRI,
Table 3
Multiple logistic regression results*
BS E S i g E x p ( B ) 8 5 %  C I
Lower Upper
ΔSVI 0.54 0.27 0.05 1.72 1.32 2.12
ΔsBP/LVESVI 0.45 0.36 0.19 1.57 1.03 2.1
Constant -5.13 2.24 0.02 0.01
Overall % Correctly Classified: 95.7% (n = 22/23)
* ΔSVI and ΔsBP/LVESVI identified as unique predictors by discriminant function analysis Structure coefficients: ΔSVI = 0.81, ΔsBP/LVESVI = 
0.46
ΔSVI and ΔsBP/LVESVI simultaneous entry with p ≤ 0.15 for inclusion and p ≤ 0.20 for model retention. Overall p = 0.00004, Χ2 = 20.16681, df 
= 2
Δ = change
Figure 1
(a) Baseline heart rate in survivors and non-survivors (a) Baseline heart rate in survivors and non-survivors. Dotted line indi-
cates optimally predictive cut-off value of 95 beats/min to differentiate 
between survivors and non-survivors. Outcome stratification was defi-
cient in only 8 of the 23 total subjects using this cut-off. Heart rate was 
the only baseline haemodynamic variable associated with outcome (p = 
0.0254). (b) Change in heart rate from baseline at the point of maximal 
cardiac output response during dobutamine challenge. Change in heart 
rate was not significantly different between survivors and non-survivors. 
Dash indicates mean value for group.
Figure 2
(a) Baseline stroke volume index in survivors and non-survivors (a) Baseline stroke volume index in survivors and non-survivors. Stroke 
volume index at baseline was not significantly different between survi-
vors and non-survivors. (b) Change in stroke volume index from base-
line at the point of maximal cardiac output response during dobutamine 
challenge. Change in stroke volume was the strongest predictor of out-
come among tested variables (p = 0.0003). A cut-off value of 8.5 mL/
m2 increase in stroke volume index (indicated by the dotted line) cor-
rectly categorised outcome in 21 of 23 subjects with only one mis-
match in each group. Dash indicates mean values.Available online http://ccforum.com/content/12/2/R35
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PVRI and dPAP. Decreases in diastolic systemic arterial pres-
sure did not reach significance in this regard.
In terms of the mechanics of cardiovascular performance,
greater increases of left ventricular contractility indices were
associated with survival in patients with septic shock (Table
2). Indices of relevance included LVEF (Figure 3), LVSWI and
parameters were not similarly associated with survival. How-
ever, increases in RVEDVI (Figure 5) and right ventricular com-
pliance (RVEDVI/RAP) either achieved or trended strongly
towards significance in association to survival (Table 2).
Using multivariate forward entry discriminant analysis, several
alternative models with similar predictive accuracy were iden-
tified depending on the significance level used to add and
retain variables in each model. In each case, the SVI response
was, by far, the most predictive variable. However, the most
parsimonious discriminant model achieved maximal accuracy
with the addition of sBP/LVESVI response as a 2nd factor in
the model. Using this model, outcome in 22 of 23 cases could
be appropriately categorised (Table 3). SVI responses were
43 per cent more predictive of outcome than sBP/LVESVI
responses in this model (ratio of structure coefficients). Other
variables associated with left ventricular contractility and right
ventricular lusitropy did not contribute to prediction of out-
come in the multivariate model. Multiple logistic model param-
eters are summarised in Table 3. Positive B coefficients in the
logistic regression model indicate that higher SVI and sBP/
LVESVI are independently indicative of increased probability
of survival. Confidence intervals indicate as much as a dou-
bling of survival odds, on average, over the range of SVI and
sBP/LVESVI responses covered by this sample [14]. Discrimi-
nant multivariate assessment of relative (indexed to baseline)
changes in responses yielded similar results.
Discussion
Dobutamine, a racemic synthetic catecholamine composed of
two enantiomers with divergent sympathetic activity, was
developed as an inotropic agent and is most commonly used
for support of patients with congestive heart failure and other
Figure 3
(a) Baseline left ventricular ejection fraction in survivors and non-survi- vors (a) Baseline left ventricular ejection fraction in survivors and non-survi-
vors. Seven of fourteen non-survivors and five of eight survivors had a 
reduced ejection fraction (less than 55 per cent). The lower mean ejec-
tion fraction in survivors did not reach statistical significance in compar-
ison to the higher ejection fraction in non-survivors. (b) Change in left 
ventricular ejection fraction from baseline at the point of maximum car-
diac index response. The mean increase in left ventricular ejection frac-
tion was significantly greater in survivors than in non-survivors (p = 
0.0160). Dash indicates mean values.
Figure 4
(a) Baseline peak systolic blood pressure/left ventricular end-systolic  volume index (sBP/LVESVI) in survivors and non-survivors (a) Baseline peak systolic blood pressure/left ventricular end-systolic 
volume index (sBP/LVESVI) in survivors and non-survivors. Baseline 
sBP/LVESVI was not significantly different between survivors and non-
survivors. (b) Change in sBP/LVESVI from baseline at the point of max-
imum cardiac output response. A significantly greater mean increase in 
sBP/LVESVI was seen in survivors (p = 0.0188). Non-survivors had 
almost no mean change in this parameter with dobutamine infusion. 
Dash indicates mean values.
Figure 5
(a) Baseline right ventricular end-diastolic volume index (RVEDVI) in  survivors and non-survivors (a) Baseline right ventricular end-diastolic volume index (RVEDVI) in 
survivors and non-survivors. Baseline RVEDVI was similar in both survi-
vors and non-survivors. (b) Change in RVEDVI from baseline at the 
point of maximum cardiac index response. The mean increase in 
RVEDVI was significantly greater in survivors than non-survivors (p = 
0.0047). Dash indicates mean values.Critical Care    Vol 12 No 2    Kumar et al.
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low output states of cardiogenic decompensation [17]. A
series of studies have assessed this compound as a potential
adjunctive therapy in severe sepsis for purposes of
augmentation of oxygen delivery [18-21]. In addition, a dob-
utamine stress test with determination of oxygen consumption
responses to assess survival potential of patients with severe
sepsis and septic shock has been examined [22-24]. No stud-
ies have assessed volumetric responses to graded dob-
utamine infusion in septic patients in relationship to outcome.
This study, like that of Jellema and colleagues [25], shows that
dobutamine infusion in patients with septic shock generates a
highly heterogenous cardiovascular response. We also dem-
onstrate that dobutamine-stressed ventricular and
cardiovascular responses are highly correlated with outcome.
The observation that greater increases in left ventricular con-
tractility (LVEF, sBP/LVESVI, LVSWI) and right ventricular lus-
itropy (RVEDVI, RVEDVI/RAP) indices are associated with
survival in severe sepsis and septic shock in univariate analy-
sis, is entirely novel. In addition, an independent contribution
to prediction of survival under dobutamine stress from
cardiovascular performance (SVI) and left ventricular contrac-
tility (sBP/LVESVI) responses has also not been previously
reported. Notably, the correlative strength of these responses
is substantially more powerful than that generated by initial
HR, the only baseline hemodynamic index to predict outcome.
These results are important for at least three reasons. First,
they support the notion that simple haemodynamic responses
to dobutamine stress can potentially differentiate between sur-
vivors and non-survivors of sepsis and septic shock. This con-
firms long-standing clinical observations and suggests that
these responses may be useful in terms of clinical prognosti-
cation for purposes of risk stratification in clinical trials. Sec-
ond, they suggest that dynamic cardiovascular responses may
be superior to static performance parameters with respect to
their association with survival. Finally, these observations pro-
vide important insights regarding the mechanism underlying
the cardiovascular response to adrenergic stimulation in survi-
vors versus non-survivors of septic shock.
The observation that only HR among all baselines haemody-
namic/oxygen metabolism variables assessed was signifi-
cantly correlated with outcome has precedence in other
studies of septic shock [4,26]. Azimi and coworkers demon-
strated that only heart rate among initial haemodynamic varia-
bles was associated with outcome with a value of less than
106 beats/min linked to survival [26]. No other initial parame-
ters were associated with prognosis. Parker and colleagues
similarly demonstrated that HR of less than 95 beats/min at
presentation was associated with survival in a study of 48
patients with septic shock [4]. There are several possibilities
to explain the association of an increased HR with a higher
probability of death. The increased HR in non-survivors may
indicate a higher level of sepsis-induced cardiovascular stress
due to a more severe disease state. Alternately, it may repre-
sent a secondary compensatory response as a consequence
of decreased sensitivity to the direct myocardial inotropic
effects of endogenous catecholamines in patient with particu-
larly severe septic myocardial dysfunction [3,27]. Given that
baseline SV and sBPVESI was similar in both groups, this pos-
sibility seems less likely. Another possibility is that non-survi-
vors have increased sensitivity to catecholamine stimulation.
This also seems unlikely since several studies have shown β-
adrenergic uncoupling in myocardial tissue exposed to inflam-
matory mediators such as those found circulating in patients
with septic shock [28,29]. Since the study was not designed
to determine the cause of this finding, no definitive conclusion
can be drawn.
Despite observations dating back several decades suggesting
that reduced response to catecholamine support in septic
shock is highly predictive of poor outcome, most recent work
examining the prognostic significance of dobutamine stress in
this situation has focused on oxygen consumption/delivery
indices [22-24]. Both Vallet et al [24] and Rhodes et al [22]
have shown that increases of oxygen consumption of greater
than 15 per cent with 10 μg/kg/min during severe sepsis are
associated with a favorable outcome. However, it is not at all
clear that it is necessary to invoke oxygen consumption/deliv-
ery responses for predictive power. Both studies clearly dem-
onstrated that cardiac index responses were also highly
associated with outcome. However, neither closely examined
cardiac performance parameters as correlates of outcome.
In our study, cardiovascular performance as indicated by SVI
response was the dominant correlate to outcome with a single
cut off value of 8.5 mL/min able to differentiate 21 of 23 out-
comes. The predictive power of most other parameters
appeared to be physiologically linked to this response and did
not persist in multivariate analysis (CI, PP, OER, PAD, SVRI,
PVRI, DO2I, MvO2, CvO2). sBP/LVESVI, a relatively load-inde-
pendent index of left ventricular contractility [30], was the only
variable that possessed predictive power independent of
stroke volume index (in analysis with both absolute and relative
changes from baseline). This response appears to statistically
dominate other contractility indices (LVEF and LVSWI) in
terms of contribution to the model. If sBP/LVESVI is removed
from the model, then LVEF becomes a significant contributor
along with SVI.
The fact that both cardiac performance and contractility
increases in response to dobutamine stress are highly associ-
ated with outcome in septic shock is consistent with the pos-
sibility that the presence of cardiovascular reserve (that is an
indication of submaximal cardiovascular response to baseline
stress) may be critical to survival. This concept of preserved
physiologic reserve as a marker of good prognosis in septic
shock has previously been postulated by Hayes et al [31] and
Rhodes et al [22] albeit in the context of oxygen consumptionAvailable online http://ccforum.com/content/12/2/R35
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indices. However, it may relate directly to cardiovascular per-
formance and contractility indices as shown in this study.
This study may also demonstrate that the concept of preload
reserve used most commonly in reference to ischemic heart
disease associated limitations in cardiac performance may
also apply to septic shock [32]. Several groups of investiga-
tors have shown that subjects with clinically asymptomatic
impairment of systolic cardiac function can be differentiated
from symptomatic patients by the presence of exercise stress-
induced increases in SVI in association with ventricular dilata-
tion [33,34]. No direct link has yet been made between sur-
vival and the presence of this phenomenon among patients
with impaired heart function. Despite this, our study may be
unmasking a parallel, related phenomenon in that both
exercise and dobutamine challenge represent stressed states
in comparison to baseline.
Similarly, our observations of an association of right ventricular
dilatation (Table 2, Figure 5a) in response to dobutamine (with
a similar trend for the left ventricle) appear to be related to our
previous observations which demonstrate a relationship
between right and left ventricular dilation and survival in septic
shock [3,8,35].
One possibility to tie these observations together is that
recruitment of preload reserve is a critical but late response
during high degrees of cardiovascular stress. If that is the
case, then a lack of ability to recruit ventricular volume at any
point during cardiovascular stress may indicate that the sub-
ject is already operating at the maximum efficacy of the Frank-
Starling response and has no additional cardiovascular
reserve. In this formulation, patients with chronic systolic dys-
function would be more likely to be symptomatic, while
patients with septic shock would be more likely to die if such
reserve was limited. The nature of the limitation of cardiovas-
cular reserve in conditions of high stress would be a combina-
tion of the baseline cardiovascular fitness and the degree of
acute cardiovascular stress.
The study demonstrates that cardiovascular hypo-responsive-
ness to catecholamine stimulation is strongly associated with
mortality in severe sepsis and septic shock. Compared to
baseline differences in heart rate, dobutamine stress-induced
variations in stroke volume responses are much more closely
related to outcome. Dobutamine-induced differences in con-
tractility responses also appear to possess independent cor-
relative power with respect to mortality. One physiological
mechanism supporting increased cardiac output appears to
involve ventricular dilatation in survivors suggesting an impor-
tant role for "preload reserve" in optimal cardiovascular
response to severe sepsis and septic shock. This response
may be related to previous observations demonstrating that
increased ventricular dilatation is characteristic of survival from
septic shock.
This study makes several novel observations. However there
are significant limitations to the results. First, despite the fact
that dobutamine-stress induced cardiovascular responses are
highly associated with outcome, their utility for risk stratifica-
tion as related to research or clinical prognostication remains
unproven. A prospective study would be required to validate
their utility for that purpose. Second, these data do not sug-
gest that any of the variables associated with outcome drive
these are responsible for these outcomes. It is much more
likely that these associations are correlations without causality.
For example, reduced stroke volume response to dobutamine
likely indicates underlying severity of illness rather than being
a direct contributor to risk of death. Finally, there may be sig-
nificant unmeasured confounders for some of the documented
responses. Higher mean intra-thoracic pressures due to more
severe lung disease and greater ventilatory requirements
could contribute to the smaller RVEDVI and RVEDVI/RAP
responses to dobutamine. These patients could also be at
higher risk of death. Unfortunately, mean airway pressures are
not available for analysis.
Conclusion
Although a variety of dobutamine-stimulated cardiovascular
and ventricular responses are associated with outcome in sep-
sis and septic shock, SVI increases are most strongly corre-
lated with survival. Since this stimulation test involves transient
administration of dobutamine, this response is probably indic-
ative of preservation of cardiac signalling mechanisms and of
cardiovascular reserve in the septic patient. Notably, the
predictive strength of these responses is substantially more
powerful than that generated by initial HR, the only baseline
haemodynamic index associated with outcome.
Further research is required to better understand the mecha-
nisms underlying differing cardiovascular responses during
severe sepsis and septic shock both at baseline and under
exogenous catecholamine stress.
Key Messages
1) Survival from sepsis and septic shock is closely associated
with dobutamine-stimulated increases in stroke volume.
2) Survivors of sepsis and septic shock are characterised by
preserved cardiovascular reserve including preload reserve.
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